Compare Shell PLC (SHEL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Shell PLC vs State Street SPDR S&P Biotech ETF — how do they compare? Shell PLC trades at $95.6 (market cap $271.34B), while State Street SPDR S&P Biotech ETF trades at $159.9. The key difference: Shell PLC pays a 3.28% dividend while State Street SPDR S&P Biotech ETF pays none, and Shell PLC is trading nearer its 52-week high, State Street SPDR S&P Biotech ETF nearer its low. Which is the better fit depends on your goals.
| SHEL | XBI | |
|---|---|---|
Market Cap | $271.34B | — |
Sector | Energy | Broad Market / Factor |
52-Week High | $95.60 | $169.55 |
52-Week Low | $70.31 | $93.43 |
Enterprise Value | $313.04B | — |
Dividend Yield | 3.28% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Shell (SHEL) trades at $95.32, up 2.55% with strong bullish momentum as crude oil prices rally. The stock shows robust fundamentals with a P/E of 10.54 and net income margin of 8.76%, while recent Q2 2026 earnings beat expectations. Technical indicators signal bullish sentiment with the price near resistance at $96. Recent acquisitions including ARC Resources and strategic partnerships with BP expand Shell's deepwater footprint, driving growth prospects.
Outlook remains positive with analyst consensus price target of $101 (6% upside), supported by 61.5% buy ratings. Key risks include oil price volatility and geopolitical tensions, but strong cash flow generation and strategic expansions position SHEL for sustained growth. The current valuation appears attractive relative to earnings potential.
XBI trades at $161.97, down 1.12% today, with technical indicators showing mixed signals amid a bearish overall trend. The ETF holds over 150 biotech companies and has rallied 76% in the past year, driven by M&A activity and positive clinical trial catalysts. Analyst coverage remains limited with a single hold rating, while recent news highlights sector optimism around cancer vaccine breakthroughs and improved capital access.
Outlook remains cautiously optimistic with potential for 8-14% returns over 6-12 months, though high volatility and regulatory risks persist. Key opportunities include ongoing pharmaceutical M&A and innovation in immunotherapy, while risks center on sector-specific volatility and policy uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
